India Achieves 1 Crore HPV Vaccination Milestone in Cervical Cancer Prevention

India's Ministry of Health and Family Welfare announced the administration of over 1 crore doses of Human Papillomavirus (HPV) vaccine under the National HPV Vaccination Campaign in less than nine months since its launch in February 2026. The campaign, initiated by Prime Minister Narendra Modi, has achieved nearly 87% cumulative coverage against the identified annual target cohort of approximately 1.2 crore 14-year-old girls based on Registrar General of India 2021 population estimates.

Six states achieved 100% coverage of their identified target populations: Gujarat, Uttar Pradesh, Andhra Pradesh, Mizoram, Madhya Pradesh, and Bihar. Uttar Pradesh leads in absolute numbers with 29.33 lakh girls vaccinated, followed by Bihar (13.70 lakh) and Gujarat (7.75 lakh). Other high-performing states include Assam (95.63%), Telangana (95.28%), Karnataka (93.16%), and Uttarakhand (90.17%), while Chhattisgarh (86.21%) and Rajasthan (85.23%) crossed 80% coverage, and Kerala (77.02%), Tamil Nadu (76.12%), Odisha (74.90%), and Dadra and Nagar Haveli and Daman and Diu (72.99%) achieved over 70% coverage.

The campaign provides free, safe, and voluntary single-dose HPV vaccination with parental consent to 14-year-old girls at designated Government health facilities. The U-WIN digital platform enables real-time monitoring, beneficiary tracking, vaccination slot booking, and digital certificates, strengthening transparency and accessibility. All vaccination sessions are conducted under the supervision of trained Medical Officers with 24×7 healthcare arrangements for management of rare Adverse Events Following Immunization (AEFI).

The initiative represents a significant advancement in India's preventive healthcare approach, supported by extensive global scientific evidence demonstrating HPV vaccine effectiveness against cervical cancer. More than 800 million HPV vaccine doses have been administered worldwide, with nearly two decades of research showing strong protection against vaccine-targeted HPV infections and associated precancerous conditions.